NZ531180A - Compositions and methods for effecting the levels of cholesterol using the LIPG polypeptide - Google Patents

Compositions and methods for effecting the levels of cholesterol using the LIPG polypeptide

Info

Publication number
NZ531180A
NZ531180A NZ531180A NZ53118000A NZ531180A NZ 531180 A NZ531180 A NZ 531180A NZ 531180 A NZ531180 A NZ 531180A NZ 53118000 A NZ53118000 A NZ 53118000A NZ 531180 A NZ531180 A NZ 531180A
Authority
NZ
New Zealand
Prior art keywords
lipg
leu
gly
ser
val
Prior art date
Application number
NZ531180A
Other languages
English (en)
Inventor
Michael Jaye
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/277,401 external-priority patent/US7008776B1/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NZ531180A publication Critical patent/NZ531180A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
NZ531180A 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol using the LIPG polypeptide NZ531180A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/277,401 US7008776B1 (en) 1996-12-06 1999-03-26 Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol

Publications (1)

Publication Number Publication Date
NZ531180A true NZ531180A (en) 2005-06-24

Family

ID=23060703

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ51435000A NZ514350A (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol
NZ531180A NZ531180A (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol using the LIPG polypeptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ51435000A NZ514350A (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol

Country Status (13)

Country Link
EP (1) EP1171078A4 (fr)
JP (1) JP2002540127A (fr)
KR (2) KR100887164B1 (fr)
AU (1) AU776684B2 (fr)
BR (1) BR0009333A (fr)
CA (1) CA2363486C (fr)
HK (1) HK1043309A1 (fr)
IL (2) IL145526A0 (fr)
MX (1) MXPA01009727A (fr)
NO (2) NO331779B1 (fr)
NZ (2) NZ514350A (fr)
WO (1) WO2000057837A2 (fr)
ZA (1) ZA200107598B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
JP5713377B2 (ja) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
JP6091752B2 (ja) 2008-12-04 2017-03-08 クルナ・インコーポレーテッド Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療
RU2618688C2 (ru) 2008-12-04 2017-05-10 КьюРНА,Инк.,US Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена
WO2010065671A2 (fr) 2008-12-04 2010-06-10 Curna, Inc. Traitement de maladies apparentées au facteur de croissance de l'endothélium vasculaire (vegf) par inhibition de la transcription antisens naturelle en vegf
HUE026280T2 (en) 2009-02-12 2016-06-28 Curna Inc Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t
US9464287B2 (en) 2009-03-16 2016-10-11 Curna, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
US9708604B2 (en) 2009-03-17 2017-07-18 Curna, Inc. Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
CN102803492B (zh) 2009-05-06 2016-06-29 库尔纳公司 通过抑制针对三重四脯氨酸(ttp)的天然反义转录物来治疗ttp相关疾病
CA2761152A1 (fr) 2009-05-06 2010-11-11 Opko Curna, Llc Traitement de maladies associees aux genes du metabolisme et du transport des lipides par inhibition de transcrit antisens naturel d'un gene du metabolisme et du transport des lipides
ES2618572T3 (es) 2009-05-08 2017-06-21 Curna, Inc. Tratamiento de enfermedades relacionadas con la familia de la distrofina mediante inhibición de un transcrito antisentido natural para la familia de dmd
US8957037B2 (en) 2009-05-18 2015-02-17 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
JP2012527248A (ja) 2009-05-22 2012-11-08 クルナ・インコーポレーテッド 転写因子ｅ３（ｔｆｅ３）に対する天然アンチセンス転写物の阻害によるｔｆｅ３およびインスリン受容体基質２（ｉｒｓ２）関連疾患の処置
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
KR101702689B1 (ko) 2009-06-16 2017-02-06 큐알엔에이, 인크. Ｐｏｎ1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(ｐｏｎ1) 관련된 질환의 치료
EP2443237B1 (fr) 2009-06-16 2017-02-22 CuRNA, Inc. Traitement de maladies liées au gène du collagène par inhibition d'un produit de transcription antisens naturel à un gène du collagène
CN102597238B (zh) 2009-06-24 2016-06-29 库尔纳公司 通过抑制针对肿瘤坏死因子受体2(tnfr2)的天然反义转录物来治疗tnfr2相关的疾病
CN102482672B (zh) 2009-06-26 2016-11-09 库尔纳公司 通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
KR101801407B1 (ko) 2009-07-24 2017-11-24 큐알엔에이, 인크. 시르투인 (ｓｉｒｔ)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
EP2462229B1 (fr) 2009-08-05 2016-05-11 CuRNA, Inc. Traitement de maladies liées à un gène de l insuline (ins) par inhibition du transcrit antisens naturel d'un gène de l'insuline (ins)
ES2599986T3 (es) 2009-08-11 2017-02-06 Curna, Inc. Tratamiento de enfermedades relacionadas con adiponectina (ADIPOQ) mediante la inhibición de un transcrito antisentido natural de una adiponectina (ADIPOQ)
EP2982755B1 (fr) 2009-08-21 2020-10-07 CuRNA, Inc. Traitement de maladies associées à l'extrémité c terminale d'une protéine interagissant avec hsp70' (puce) par inhibition du transcrit antisens naturel de puce
US9023822B2 (en) 2009-08-25 2015-05-05 Curna, Inc. Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
CN102791861B (zh) 2009-09-25 2018-08-07 库尔纳公司 通过调节聚丝蛋白(flg)的表达和活性而治疗flg相关疾病
KR101823702B1 (ko) 2009-12-16 2018-01-30 큐알엔에이, 인크. 막 결합 전사 인자 펩티다제, 부위 １(ｍｂｔｐｓ１)에 대한 천연 안티센스 전사체의 억제에 의한 ｍｂｔｐｓ１ 관련 질환의 치료
KR101793753B1 (ko) 2009-12-23 2017-11-03 큐알엔에이, 인크. 커플링방지 단백질 ２(ｕｃｐ２)에 대한 천연 안티센스 전사체의 저해에 의한 ｕｃｐ２ 관련 질환의 치료
DK2516648T3 (en) 2009-12-23 2018-02-12 Curna Inc TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF
KR101838305B1 (ko) 2009-12-29 2018-03-13 큐알엔에이, 인크. ＮＲＦ1(Ｎｕｃｌｅａｒ Ｒｅｓｐｉｒａｔｏｒｙ Ｆａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
CN102770540B (zh) 2009-12-29 2017-06-23 库尔纳公司 通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病
RU2616283C2 (ru) 2009-12-31 2017-04-13 Курна, Инк. Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2
RU2611187C2 (ru) 2010-01-04 2017-02-21 Курна, Инк. Лечение заболеваний, связанных с интерферон-регуляторным фактором 8 (irf8), путем ингибирования природного антисмыслового транскрипта к irf8
CA2786056C (fr) 2010-01-06 2023-03-14 Curna, Inc. Traitement de maladies associees a un gene de developpement pancreatique par inhibition du produit de la transcription anti-sens naturel en un gene de developpement pancreatique
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
US8946182B2 (en) 2010-01-25 2015-02-03 Curna, Inc. Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
CN102844435B (zh) 2010-02-22 2017-05-10 库尔纳公司 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
ES2657969T3 (es) 2010-04-02 2018-03-07 Curna, Inc. Tratamiento de enfermedades relacionadas con el Factor 3 estimulante de colonias (CSF3) por inhibición del transcrito antisentido natural a CSF3
CN102858979B (zh) 2010-04-09 2018-01-26 库尔纳公司 通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
KR101936011B1 (ko) 2010-05-03 2019-01-07 큐알엔에이, 인크. 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
EP3299464B1 (fr) 2010-05-26 2019-10-02 CuRNA, Inc. Traitement de maladies associées à l'homologue atonal 1 par inhibition du produit de transcription antisens naturel d'atoh1
CN102971423B (zh) 2010-05-26 2018-01-26 库尔纳公司 通过抑制蛋氨酸硫氧化物还原酶a(msra)的天然反义转录物而治疗msra相关疾病
US9771579B2 (en) 2010-06-23 2017-09-26 Curna, Inc. Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA
CA2805318A1 (fr) 2010-07-14 2012-01-19 Curna, Inc. Traitement de maladies liees a « discs large homolog » (dlg) par inhibition de transcrit antisens naturel de dlg
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
JP6049623B2 (ja) 2010-10-22 2016-12-21 カッパーアールエヌエー，インコーポレイテッド α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
WO2012068340A2 (fr) 2010-11-18 2012-05-24 Opko Curna Llc Compositions d'antagonat et leurs méthodes d'utilisation
JP6071893B2 (ja) 2010-11-23 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Ｎａｎｏｇへの天然アンチセンス転写物の阻害によるｎａｎｏｇ関連疾患の治療
US9593330B2 (en) 2011-06-09 2017-03-14 Curna, Inc. Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
CA2847811C (fr) 2011-09-06 2019-10-22 Curna, Inc. Traitement de maladies liees a des sous-unites alpha de canaux sodiques voltage-dependants (scnxa) avec de petites molecules
KR20140136488A (ko) 2012-03-15 2014-11-28 큐알엔에이, 인크. 뇌 유래 신경영양 인자（ｂｄｎｆ）에 대한 천연 안티센스 전사체의 저해에 의한 뇌 유래 신경영양 인자（ｂｄｎｆ）관련 질환의 치료
CN102628060A (zh) * 2012-03-22 2012-08-08 北京济福霖生物技术有限公司 一种低脂奶的生产方法
US9695462B2 (en) 2012-11-05 2017-07-04 Shionogi & Co., Ltd. Method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity and a method for screening an inhibitor of EL activity
US9701757B2 (en) * 2013-03-14 2017-07-11 Shionogi & Co., Ltd. Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
TWI688575B (zh) 2014-09-11 2020-03-21 日商塩野義製藥股份有限公司 阻礙血管內皮脂酶之酵素活性的人類化單株抗體
EP4284335A1 (fr) 2021-02-01 2023-12-06 RegenxBio Inc. Thérapie génique de céroïdes-lipofuscinoses neuronales
EP4378480A1 (fr) * 2021-07-26 2024-06-05 Purotech Bio, Inc. Agent anti-virus de l'hépatite b ciblant le facteur hôte lipg

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679525B2 (en) * 1992-12-04 1997-07-03 Innovir Laboratories, Inc. Regulatable nucleic acid therapeutic and methods of use thereof
CN100497610C (zh) * 1996-12-06 2009-06-10 阿温蒂斯药物公司 人脂酶样基因编码的多肽及利用它的组合物和方法
WO1999032611A1 (fr) * 1997-12-19 1999-07-01 Progenitor, Inc. Lipase exprimee dans des cellules endotheliales et procedes d'utilisation associes

Also Published As

Publication number Publication date
EP1171078A2 (fr) 2002-01-16
NO331779B1 (no) 2012-03-26
MXPA01009727A (es) 2002-07-22
KR20020029651A (ko) 2002-04-19
WO2000057837A2 (fr) 2000-10-05
WO2000057837A8 (fr) 2001-09-27
ZA200107598B (en) 2003-05-28
IL145526A0 (en) 2002-06-30
KR20050044812A (ko) 2005-05-12
NO331784B1 (no) 2012-03-26
IL145526A (en) 2010-11-30
AU776684B2 (en) 2004-09-16
CA2363486A1 (fr) 2000-10-05
NO20014657L (no) 2001-11-21
NO20014657D0 (no) 2001-09-25
BR0009333A (pt) 2002-01-08
NO20100214L (no) 2001-11-21
KR100887164B1 (ko) 2009-03-10
WO2000057837A3 (fr) 2001-01-25
NZ514350A (en) 2004-12-24
EP1171078A4 (fr) 2002-11-06
HK1043309A1 (zh) 2002-09-13
WO2000057837A9 (fr) 2001-10-18
CA2363486C (fr) 2012-12-18
JP2002540127A (ja) 2002-11-26
AU3918700A (en) 2000-10-16

Similar Documents

Publication Publication Date Title
AU776684B2 (en) Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI, very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US7008776B1 (en) Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US8343494B2 (en) Antibodies against LLG polypeptides of the triacylglycerol lipase family
WO1998024888A9 (fr) Polypeptides llg de la famille des triacylglycerol lipases, compositions et procedes destines a l'utilisation de ceux-ci dans des hydrolyses enzymatiques, et therapies geniques et protidiques

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: AVENTIS PHARMACEUTICALS INC, US

Free format text: OLD OWNER(S): AVENTIS PHARMACEUTICALS INC.; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

PSEA Patent sealed
S35A Application for proceedings under section 35 (restoration of lapsed patents)
RENW Renewal (renewal fees accepted)
S35R Proceedings under section 35 (restoration of lapsed patents): patent restored
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 24 MAR 2020 BY CPA GLOBAL

Effective date: 20130211

EXPY Patent expired